Daré Bioscience, Inc.
DARE
$0.72
$0.011.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 984.43% | 500.39% | 1,709.59% | -94.48% | -194.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 984.43% | 500.39% | 1,709.59% | -94.48% | -194.64% |
| Cost of Revenue | -60.67% | -60.70% | 58.04% | -56.18% | -- |
| Gross Profit | 74.18% | 66.98% | -48.42% | 55.57% | -6,572.77% |
| SG&A Expenses | 9.08% | -2.62% | -20.99% | 22.43% | -2.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.10% | -31.59% | -53.14% | -22.20% | -48.43% |
| Operating Income | 22.46% | 34.54% | 72.69% | 21.56% | 47.99% |
| Income Before Tax | 25.74% | 31.48% | 73.82% | 24.24% | -131.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.74% | 31.48% | 73.82% | 24.24% | -131.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.74% | 31.48% | 73.82% | 24.24% | -131.11% |
| EBIT | 22.46% | 34.54% | 72.69% | 21.56% | 47.99% |
| EBITDA | 28.98% | 44.52% | 82.59% | 31.71% | 54.06% |
| EPS Basic | 55.76% | 58.67% | 85.30% | 49.31% | -129.50% |
| Normalized Basic EPS | 55.76% | 58.67% | 85.30% | 49.30% | -129.50% |
| EPS Diluted | 55.76% | 58.67% | 70.69% | 49.18% | -129.79% |
| Normalized Diluted EPS | 55.76% | 58.67% | 85.30% | 49.30% | -129.73% |
| Average Basic Shares Outstanding | 67.84% | 65.80% | 78.14% | 49.46% | 5.47% |
| Average Diluted Shares Outstanding | 67.84% | 65.80% | 78.14% | 49.46% | 4.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |